​

Aytu BioPharma (AYTU) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

AYTU Stock Rating

Aytu BioPharma stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 5 Strong Sell Sell Hold Buy Strong Buy

AYTU Price Target Upside V Benchmarks

TypeNameUpside
StockAytu BioPharma-
SectorHealthcare Stocks 15.45%
IndustrySpecialty & Generic Drug Manufacturers Stocks22.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$2.03$2.03$2.03
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 2512---3
Oct, 2512---3
Sep, 2512---3
Aug, 2511---2
Jul, 2511---2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change

Financial Forecast

EPS Forecast

$-75 $-59 $-43 $-27 $-11 $5 Jun 21 Jun 22 Jun 23 Jun 24 Jun 25 Jun 26 Jun 27
Jun 21Jun 22Jun 23Jun 24Jun 25Jun 26Jun 27
Reported$-69.60$-74.01$-5.11$-2.86$-2.16--
Avg Forecast$-56.80$-66.60$-6.16$-2.49$0.60$0.55$1.46
High Forecast$-56.80$-66.60$-6.16$-2.49$0.60$0.55$1.46
Low Forecast$-56.80$-66.60$-6.16$-2.49$0.60$0.55$1.46
Surprise %22.54%11.13%-17.05%14.86%-460.00%--

Revenue Forecast

$65M $74M $83M $92M $101M $110M Jun 21 Jun 22 Jun 23 Jun 24 Jun 25 Jun 26 Jun 27
Jun 21Jun 22Jun 23Jun 24Jun 25Jun 26Jun 27
Reported$65.63M$96.67M$107.40M$81.00M$66.38M--
Avg Forecast$66.15M$94.90M$104.36M$81.33M$70.35M$69.61M$69.33M
High Forecast$66.15M$94.90M$104.36M$81.33M$70.35M$69.61M$69.33M
Low Forecast$66.15M$94.90M$104.36M$81.33M$70.35M$69.61M$69.33M
Surprise %-0.78%1.86%2.91%-0.40%-5.64%--

Net Income Forecast

$-400M $-310M $-220M $-130M $-40M $50M Jun 21 Jun 22 Jun 23 Jun 24 Jun 25 Jun 26 Jun 27
Jun 21Jun 22Jun 23Jun 24Jun 25Jun 26Jun 27
Reported$-58.29M$-108.78M$-17.05M$-15.84M$-13.56M--
Avg Forecast$-314.67M$-368.96M$-34.11M$-7.28M$3.32M$3.05M$8.09M
High Forecast$-314.67M$-368.96M$-34.11M$-5.82M$3.32M$3.05M$8.09M
Low Forecast$-314.67M$-368.96M$-34.11M$-8.73M$3.32M$3.05M$8.09M
Surprise %-81.48%-70.52%-50.02%117.70%-508.15%--

AYTU Forecast FAQ

Is Aytu BioPharma stock a buy?

Aytu BioPharma stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Aytu BioPharma is a favorable investment for most analysts.

What is Aytu BioPharma's price target?

Aytu BioPharma's price target, set by 5 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $2.03.

How does Aytu BioPharma stock forecast compare to its benchmarks?

Aytu BioPharma's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the specialty & generic drug manufacturers stocks industry (22.48%).

What is the breakdown of analyst ratings for Aytu BioPharma over the past three months?

  • November 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Aytu BioPharma’s EPS forecast?

Aytu BioPharma's average annual EPS forecast for its fiscal year ending in June 2026 is $0.55, marking a -125.46% decrease from the reported $-2.16 in 2025. Estimates for the following years are.

What is Aytu BioPharma’s revenue forecast?

Aytu BioPharma's average annual revenue forecast for its fiscal year ending in June 2026 is $69.61M, reflecting a 4.86% increase from the reported $66.38M in 2025. The forecast for.

What is Aytu BioPharma’s net income forecast?

Aytu BioPharma's net income forecast for the fiscal year ending in June 2026 stands at $3.05M, representing a -122.46% decrease from the reported $-13.562M in 2025. Projections indicate .